NCT06943664View on ClinicalTrials.gov

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2028

Conditions
Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaRefractory Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

BIOLOGICAL

Cemiplimab

Given IV

BIOLOGICAL

Cetuximab Sarotalocan Sodium

Given IV

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

OTHER

Electronic Health Record Review

Ancillary studies

PROCEDURE

Endobronchial Ultrasound Bronchoscopy

Undergo EBUS

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Photoimmunotherapy

Undergo EB-PIT

PROCEDURE

Photoimmunotherapy

Undergo I-PIT

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

PROCEDURE

Robotic Bronchoscopy

Undergo robotic bronchoscopy

PROCEDURE

Video-Assisted Thoracic Surgery

Undergo VATS

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
collaborator

Rakuten Medical, Inc.

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER